See more : Para Light Electronics Co., Ltd. (6226.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Panbela Therapeutics, Inc. (PBLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Panbela Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Feiyang International Holdings Group Limited (1901.HK) Income Statement Analysis – Financial Results
- Wright Investors’ Service Holdings, Inc. (IWSH) Income Statement Analysis – Financial Results
- New Sources Energy N.V. (NSE.AS) Income Statement Analysis – Financial Results
- CAE Inc. (CAE) Income Statement Analysis – Financial Results
- Nanning Department Store Co., Ltd. (600712.SS) Income Statement Analysis – Financial Results
Panbela Therapeutics, Inc. (PBLA)
About Panbela Therapeutics, Inc.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36M | 973.81K | 1.23M | 699.76K |
| Cost of Revenue | 25.65M | 35.73M | 10.01M | 5.75M | 4.32M | 3.89M | 6.02M | 5.17M | 5.44M | 595.15K | 558.47K | 691.80K | 550.54K |
| Gross Profit | -25.65M | -35.73M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | 761.84K | 415.35K | 540.90K | 149.21K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 56.14% | 42.65% | 43.88% | 21.32% |
| Research & Development | 20.61M | 28.05M | 5.42M | 2.51M | 2.35M | 1.78M | 2.59M | 2.50M | 2.85M | 2.37K | 279.79K | 0.00 | 0.00 |
| General & Administrative | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.81M | 837.24K | 329.88K | 258.10K | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -217.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.03M | 6.04M | 4.59M | 3.25M | 1.97M | 2.11M | 3.42M | 2.66M | 2.59M | 837.24K | 329.88K | 258.10K | 253.72K |
| Other Expenses | 0.00 | -682.00K | -602.00K | 605.00K | -99.00K | -508.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 253.72K |
| Operating Expenses | 25.65M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 837.24K | 609.67K | 258.10K | 253.72K |
| Cost & Expenses | 51.29M | 34.09M | 10.01M | 5.75M | 4.32M | 3.84M | 6.02M | 5.17M | 5.44M | 1.43M | 1.17M | 949.90K | 804.26K |
| Interest Income | 123.00K | 14.00K | 1.00K | 17.00 | 2.19K | 0.00 | 1.00K | 2.00K | 8.00K | 4.00K | 18.41K | 0.00 | 0.00 |
| Interest Expense | -317.00K | 288.00K | 11.00K | 17.00K | 2.19M | 1.81M | 1.62M | 180.00K | 183.00K | 35.53K | 35.89K | 36.14K | 34.27K |
| Depreciation & Amortization | 0.00 | 16.36K | 10.01K | 5.75K | 4.32K | 3.89K | 6.02K | 5.17K | 8.00K | 9.58K | 8.79K | 5.64K | 3.10K |
| EBITDA | -51.29M | -34.76M | -10.61M | -5.15M | -4.42M | -1.76M | -6.02M | -5.17M | -5.12M | -75.40K | -194.32K | 289.44K | -101.40K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -4.56% | -17.16% | 23.40% | -14.49% |
| Operating Income | -51.29M | -34.09M | -10.01M | -5.75M | -4.32M | -3.89M | -6.02M | -5.17M | -5.44M | -75.40K | -194.32K | 282.80K | -104.50K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -5.56% | -19.95% | 22.94% | -14.93% |
| Total Other Income/Expenses | 25.85M | -956.00K | -613.00K | 691.00K | -2.29M | -2.27M | -4.89M | -285.00K | -564.00K | -31.53K | -17.48K | -35.14K | -33.69K |
| Income Before Tax | -25.45M | -35.05M | -10.62M | -5.06M | -6.62M | -6.16M | -10.91M | -5.45M | -5.68M | -106.92K | -211.80K | 247.66K | -138.20K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.88% | -21.75% | 20.09% | -19.75% |
| Income Tax Expense | -186.00K | -116.00K | -488.00K | -295.00K | -415.00K | -254.00K | -536.00K | -341.00K | -756.00K | 121.00 | 220.00 | 284.00 | 115.00 |
| Net Income | -25.26M | -34.93M | -10.14M | -4.77M | -6.20M | -5.91M | -10.37M | -5.11M | -4.93M | -107.04K | -212.02K | 247.38K | -138.31K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -7.89% | -21.77% | 20.07% | -19.77% |
| EPS | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| EPS Diluted | -232.43K | -40.75K | -20.77K | -14.80K | -26.10K | -1.52K | -3.49K | -1.97K | -4.20K | -892.03 | -1.77K | 2.06K | -1.15K |
| Weighted Avg Shares Out | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
| Weighted Avg Shares Out (Dil) | 108.69 | 857.28 | 487.88 | 322.20 | 237.51 | 3.89K | 2.97K | 2.59K | 1.17K | 120.00 | 120.00 | 120.00 | 120.00 |
Panbela Announces Closing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the closing of its previously announced public offering of (i) 4,375,000 shares...
Acceptance of Ivospemin (SBP-101) Abstract for Poster Presentation at American Association for Cancer Research (AACR)
MINNEAPOLIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for SBP-101, a proprietary polyamine analogue, has been...
Why Is Panbela Therapeutics (PBLA) Stock Down 63% Today?
Panbela Therapeutics (NASDAQ: PBLA ) stock is falling on Monday after the clinical-stage biopharmaceutical company revealed the pricing of a public offering for its shares. Panbela Therapeutics is selling 4,375,000 shares of its common stock for $2.06 each.
Panbela Announces Pricing of Approximately $9.0 Million Public Offering
MINNEAPOLIS, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pricing of a public offering of (i) 4,375,000...
Panbela Exceeds 50% Enrollment for Aspire Trial in Pancreatic Cancer, Exceeding Anticipated Timelines with Accelerated Momentum
MINNEAPOLIS, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has reached 50% enrollment for its ASPIRE global...
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial
A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy may provide therapeutic benefits to heavily pretreated patients with neuroblastoma. A Phase 1 clinical study showed that high dose DFMO treatment in combination with chemotherapy...
Panbela Announces 1-for-20 Reverse Stock Split Effective January 18, 2024
MINNEAPOLIS, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will implement the previously announced and stockholder approved 1-for-20 reverse...
PRISM BIOTECH IN MOTION: FDA APPROVAL FOR PANBELA THERAPEUTICS PEDIATRIC CANCER DRUG; SHARES JUMP 120%
New York, December 20, 2023 – PRISM MarketView, a leading provider of unbiased market insight and company news, today highlights Panbela Therapeutics, Inc. which has announced that US WorldMeds®1 (USWM) has received FDA approval of its New Drug Application (NDA) for the...
Panbela Therapeutics' stock tumbles, after more than tripling the past 2 days
Shares of Panbela Therapeutics Inc. PBLA, +55.45% dropped 21.7% in premarket trading, as they paused after a two-day “meme”-like rally of 243.5%. The two-day rally in the biopharmaceutical company's stock, which followed a record-low close of 45.7 cents on Friday,...
Panbela Therapeutics' stock skyrockets after positive FDA news on child cancer treatment
Shares of Panbela Therapeutics Inc. skyrocketed again Tuesday, following positive news from the U.S. Food and Drug Administration regarding a treatment for child cancer.
Source: https://incomestatements.info
Category: Stock Reports